A diagnostics company behind one of the best-known rapid Covid-19 tests has put its point-of-care testing unit up for sale, aiming at a valuation of $1.5bn, as private equity buyers eye opportunities in the healthcare and life sciences sectors.

Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP. Following the close of the transaction, Biocare is now part of Agilent’s Life Sciences and Diagnostics Markets Group.

Original from: Bio-Techne Corporation Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation (NASDAQ: TECH), a Minneapolis-based global provider of life scie..

Not every assay needs the same substrate. But every assay needs the right one. Kementec’s TMB Crew is a complete portfolio of chromogenic HRP substrates developed to support different ELI..

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).

Original from: Quest Diagnostics Quest Diagnostics® (NYSE: DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinica..

4.3.3 Future Status of Blood Typing Reagent Market Accompanied with further expansion of coverage of automated blood typing instrument market, promotion of newborn test, genotyping, and other new test items will..

Revvity, Inc. (NYSE: RVTY) announced the continued evolution of artificial intelligence across its Revvity Signals software business with new and expanding AI capabilities. Built natively into the Signals One™ platform, new capabilities from Signals AI help scientists transform connected R&D data into understanding, decisions and action using natural language within their existing workflows.

Original from: Masimo Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, today announced FDA 510(k) clearance for an opioi..

Original from: Fierce Biotech French biopharma Sanofi has inked a partnership deal with Pangaea Data to use its AI platform that helps detect Alpha-1 Antitrypsin Deficiency (AATD), which will be distribu..

Snibe's Clinical Chemistry Analysis System Receives CDC Certification On June 16, the Total Glycerides (TG) assay on Snibe's clinical chemistry analysis system successfully passed the CDC-CRMLN certifica..

Original from: PR Newswire Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tes..

Original from: DiaSorin Diasorin (FTSE MIB: DIA) announced today that it has received 510(k) clearance and CLIA waiver from the U.S. Food and Drug Administration (FDA) for its Group A Streptococcus (GAS)..

4.3 Market Conditions of Blood Typing Reagents 4.3.1 Market Size of China’s Blood Typing Reagent between 2024 and 2025 According to the network statistics, market size of China’s blood group reag..

Original from: PR Newswire Nivi, Inc., a digital health innovator specializing in personalized healthcare guidance and consumer insights, and MSD (known as Merck Sharp & Dohme LLC in the United State..

Original from: Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the VENTANAⓇ PTEN (SP218) RxDx Assay is the first immunohistochemistry (IHC) companion diagnostic test to receive U.S. F..

Original from: business wire Cepheid, a Danaher company, today announced it has donated an initial shipment of Xpert® Hemorrhagic Fever panel tests to support the diagnostic response to the Ebola Bun..

Original from: Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the European Union In Vitro Diagnostic Regulation (IVDR) approval of several label expansions for the VENTANA® MMR RxDx Panel, ..

Original from: Guardant Health Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx..

Original from: Danaher Danaher Corporation (NYSE: DHR), a global science and technology innovator, announced today that it has completed the acquisition of Masimo Corporation, a leading specialty diagnos..